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Summary Two hundred and eighty-four patients with advanced Hodgkin's disease (HD) (stage II with poor
prognostic features and stage III/IV) have been treated with the ChlVPP combination chemotherapy regimen
(chlorambucil, vinblastine, procarbazine and prednisolone) in a single-centre unselected series. Median follow
up is 92 months. Fifty-five patients had previously received radiotherapy but none had received previous
chemotherapy. Eighty-five per cent of previously untreated patients and 91% of previously irradiated patients
entered complete remission (CR); 71% and 68% of these respectively remain in CR at 10 years and 65% and
64% of each group respectively are alive at 10 years. On univariate analysis, age, stage, site of visceral disease
and lymphocyte count predicted survival and on multivariate analysis age, absence of symptoms, absence of
lung, liver or bone marrow disease and achieving a CR remained important predictors of survival. Acute
toxicity was mild. The 10 year actuarial risk of acute leukaemia was 2.7%. This study adds further support to
the view that chlorambucil is as effective and less toxic than mustine in combination chemotherapy for HD.
We suggest that MOPP chemotherapy is no longer routinely indicated for HD.
The successful introduction of the MOPP combination
chemotherapy regimen in 1964 at the National Cancer Insti-
tute (US) has proved to be a huge step forward in the
treatment of Hodgkin's disease (De Vita et al., 1980; Longo
et al., 1986). The complete remission rate of 84% with
overall survival of 48% for a group of patients, most of
whom had advanced disease, remains the standard by which
alternative treatments for Hodgkin's disease must be meas-
ured. Nevertheless, there are substantial residual problems
with the chemotherapy of Hodgkin's disease. Its efficacy is
still limited and 40-50% of patients either fail to enter
complete remission or relapse after chemotherapy with
MOPP. The toxicity of MOPP and related combinations is
substantial with acute haematological, gastroenterological
and neurological toxicity followed by long term gonadal
toxicity and the development of second malignancies, partic-
ularly acute myeloid leukaemia (Selby et al., 1987). For the
past 20 years, research on the chemotherapy of Hodgkin's
disease has sought to reduce the toxicity and increase the
efficacy of chemotherapy regimens.
In 1975 we introduced the ChlVPP (chlorambucil, vinblas-
tine, procarbazine and prednisolone) regimen at the Royal
Marsden Hospital. In our practice this superseded a MOPP-
based regimen known as MVPP in which vincristine was
replaced with vinblastine. Analyses in 1977 and 1982 sug-
gested that the ChlVPP regimen was an effective low-toxicity
combination chemotherapy for Hodgkin's disease (McElwain
et al., 1977; Dady et al., 1982). Moreover, a randomised
prospective trial compared chlorambucil-based combination
chemotherapy with mustine-based combination chemo-
therapy and concluded that the regimens were of comparable
efficacy (British National Lymphoma Investigation, 1986). In
this report, we describe the long term efficacy and toxicity of
the ChlVPP regimen in 284 adults who had received no
previous chemotherapy for their Hodgkin's disease.
Patients and methods
Between January 1975 and March 1986, 284 patients were
treated with ChlVPP combination chemotherapy including 55
who had received previous radiotherapy. No patients had
received previous chemotherapy. Follow-up was available on
274 patients to January 1989. Ten patients have follow-up
for less than two years having left the UK and these are
censored in the analysis at the point of last visit to RMH. All
patients were seen and treated at the Royal Marsden Hos-
pital, Sutton and represent an unselected series of patients
referred to that hospital. During the period of this study
between November 1981 and January 1983 patients were
entered into a separate study in which procarbazine was
replaced by etoposide in the regimen (the OPEC regimen).
During the period of the OPEC study all patients were
entered in an unselected way and no excluded patients
received the ChlVPP regimen alone. From March 1986
ChlVPP ceased to be the uniform first choice chemotherapy
at the hospital. Patients who received ChlVPP after March
1986 were selected according to patient or physician
preference and are not included in this series. Children of age
less than 16 years were excluded and are the subject of a
previous report (Robinson et al., 1984).
All records were reviewed retrospectively and for each
reviewer at least 10% of the findings were independently
checked by one other reviewer. If more than 5% of the
findings of a single contributor were in disagreement with the
second reviewer, a complete reanalysis of those patients was
performed. Bulk of disease at peripheral sites was defined as
masses greater than 5 cm and bulk in the mediastinum was
defined as a ratio of the maximum diameter of the mass to
the maximum diameter of the thorax of greater than 33%.
Haematological and biochemical tests were recorded and the
records of all imaging tests were reviewed. Histology was
reviewed for all patients at RMH. Histological classification
was by the criteria of Lukes and Butler (1966), and staging
was according to the Ann Arbor System (Carbone et al.,
1971). Toxicity according to WHO scales (World Health
Organization, 1979) was retrospectively analysed by review of
the hospital records.
Patients were assessed by a full clinical history and
physical examination, full blood count, erythrocyte sediment-
ation rate, serum biochemistry and liver function tests, chest
X-ray, lymphogram and bone marrow aspirates with
trephine. CT scan of the mediastinum and abdomen, hepatic
ultrasound and isotope liver scan, gallium scan and staging
laparotomy were performed only when clinically indicated. A
staging laparotomy was performed in 104 of 229 previously
untreated patients and 6 of 55 who had had previous
radiotherapy. During treatment, patients were reassessed
prior to each course of ChIVPP by physical examination,
chest X-ray, abdominal X-ray, and full blood count. At the
end of chemotherapy patients were restaged by repeating all
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investigations which had been found to be abnormal before
chemotherapy was given. The timing of complete remission is
therefore defined by physical examination and the interim
investigations but the proportion of patients entering com-
plete remission is defined by full restaging investigations. A
complete remission is defined as a return to normal for all
findings on examination and on repeat of all previously
abnormal investigations. The significance of an abnormal
mediastinal contour on chest X-ray may present great
difficulty in interpretation and is discussed below.
For patients who have relapsed from previous
radiotherapy, the Ann Arbor Staging System should not be
applied directly and it was not designed for this purpose
(Carbone et al., 1971). In attributing stages to such patients,
we have used the Ann Arbor recommendations but included
all known sites of disease (before and after radiotherapy) in
the estimation of stage. These allocations of 'cumulative
stage' at relapse must be distinguished from stage at present-
ation.
Selection ofpatients for chemotherapy and radiotherapy
The indications for chemotherapy employed at RMH in the
period 1975-1986 were consistent. However, the addition of
radiotherapy was not defined by the stage. The addition of
radiotherapy to sites of bulky disease was usual but not
invariable in patients with stage III or IV disease and the use
of extended field radiotherapy after chemotherapy in stage I
and II disease was usual but not invariable. All patients with
stage IV disease who had not had previous radiotherapy
received chemotherapy and radiotherapy was added to sites
of bulky disease in 8 cases. All patients with clinical stage III
disease and patients with pathological stage III with splenic
disease received chemotherapy first and this was followed by
radiotherapy in 28 of 83 cases. Patients with stage I and II
disease of poor prognosis (B symptoms, bulky disease, >3
nodal sites, 'E' extra nodal extension) received chemotherapy
first and this was followed by radiotherapy in 65 of 84 cases.
Treatment regimen
Days 1-14 inclusive: chlorambucil 6 mgm-2 per day orally
(not exceeding 10 mg per day); procarbazine 100 mg m-2 per
day orally (not exceeding 150 mg per day); prednisolone
40 mg per day orally. Days 1 and 8: vinblastine 6mgm2
intravenously (not exceeding 10mg per single dose).
Treatment was repeated every 4 weeks with one week's
delay if the leucocyte count was less than 3 x 109 1-', the
neutrophil count was less than 1.5 x 109 1-' or platelets were
less than 100 x 109 1- l. Vinblastine was reduced to 3 mg m-2
if grade II neuropathy developed. The number of treatment
cycles was judged according to the response of the patient.
Patients were treated to complete remission plus at least two
further cycles. In the first few years of the study, more
prolonged treatment beyond remission was employed in 38
patients (see below).
Radiotherapy
Radiotherapy started 6 weeks after the last course of
chemotherapy. The extended field (mantle, inverted Y or
total nodal) appropriate to the extent of the disease at pres-
entation was treated with 35 Gy mid plain dose in 20 frac-
tions per 4 week course. Fifty-three patients received mantle
radiotherapy, 13 patients mantle plus para aortic strip, eight
patients inverted Y and 39 patients total nodal irradiation.
Fifteen patients received modified field radiotherapy to the
same dose.
Statistical methods
Differences in patient characteristics and comparisons of
complete remission rates were evaluated using the x2 test with
Yates' correction for categorical variables, or the
Mann-Whitney rank test where one factor is continuous.
Survival duration and relapse-free interval for patients who
achieved complete remission were both measured from the
date of first chemotherapy. The curves presented were cal-
culated using the method of Kaplan and Meier (1978) and
the log rank test (Peto et al., 1977) was used to compare the
curves. The percentages of patients remaining in remission
and surviving at 5 and 10 years given in Tables I and II are
obtained from such curves. For continuous variables,
different groupings were examined to determine those which
most influenced survival and remission durations. A stepwise
linear regression analysis based on Cox's proportional
hazards model (Cox, 1972) was performed to assess the
relative importance of the various factors in determining the
survival duration and relapse-free interval for this group of
patients.
Results
Patient characteristics
Table I includes the basic demographic and clinical features
of the 229 patients who had had no previous treatment. In
Table II abbreviated data are given for 55 patients who had
relapsed from previous radiotherapy. The median follow-up
for surviving patients is 92 months.
Treatment
The median number of courses for all patients was 6 (range
1-16) and 174 of 284 patients received 6 courses. Seven
patients received 7 courses; 14 received 8 courses; 4 received
9 courses; 12 received 10 courses and 1 received 16 courses.
One hundred and twenty-eight previously untreated patients
received elective radiotherapy following their chemotherapy.
Efficacy
Tables I and II give complete remission rates together with
the observed probability of continuing remission and survival
at 5 and 10 years after treatment. The overall CR rate was
85% (no previous treatment) and 91% (previous
radiotherapy). The 10 years probability of survival was 65%
and 67% for these two groups respectively and 20-25% of
CR patients relapsed. Duration of remission and survival
curves are shown in Figures 1 and 2. The overall survival and
relapse curves for patients who had no previous treatment
and those who had previous radiotherapy are similar (Figure
la and b).
Among 128 patients who received radiotherapy after
chemotherapy the CR rate was 95% while among 101
patients who received chemotherapy alone the CR rate was
71%. However, the policy in patients who failed to remit on
ChlVPP chemotherapy was to switch to alternative chemo-
therapy regimens, which means that the selection of cases for
the no-radiotherapy group was influenced by their response
and the difference between the two groups is inevitably
biased. There were 21 patients within the group who received
elective radiotherapy after chemotherapy who entered CR
after receiving combined modality treatment but were not felt
to be in CR after the chemotherapy. Fourteen of these had
residual abnormalities of the mediastinal contour after shrin-
kage of bulky mediastinal disease and the true significance of
this remains uncertain. The remaining 7 had residual disease
at other sites after chemotherapy.
For previously untreated patients Table III summarises the
results of a univariate analysis to examine the influence of all
of the factors listed in Table I as well as ESR, haemoglobin,
alkaline phosphatase, hepatic transaminase, gamma glutamyl
transpeptidase on CR, relapse and survival. The important
prognostic factors which emerged from this analysis for the
previously untreated group of patients are given below.
Age (Figure 2a and b). The age distribution is unremark-
able for HD with median 30, range 16-81. The main prog-
ChlVPP FOR HODGKIN'S DISEASE 281
Table I 229 no previous treatment ChlVPP patients
Remaining in
No. remission Survival
No. CR 5 years 10 years 5 years 10 years
patients (%) % % %
Total 229
Sex Male 152
Female 77
Histology LD 10
LP 12
MC 70
NS 137
Clinical Stage I 27
II 89
III 64
IV 49
Final Stage I 13
(after LAP) II 71
III 83
IV 62
B Symptoms No 117
Yes 112
Age < 26 74
26-39 88
40-59 43
60 + 24
Lung No 197
Yes 16
Early 16
Liver No 193
Yes 36
Bone No 220
marrow Yes 9
Lung, Liver, Yes 53
bone marrow No 176
Bone No 224
Yes 5
Pleural No 207
effusion Yes 22
Spleen No 139
Yes 90
Mediastinum No 117
Yes 111
Bulky No 51
mediastinum Yes 58
No of nodal 0-3 126
sites > 3 103
Bulky nodes No 106
1 103
>1 20
Response CR 194
Non CR 35
194 (85%) 74.4
126 (83%) 72.1
68 (88%) 78.7
8 (80%) 75.0
9 (75%) 41.7
62 (89%) 83.2
115 (84%) 72.1
26 (96%) 75.2
78 (88%) 79.4
55 (86%) 68.6
35 (71%) 71.3
12 (92%) 90.C
62 (87%) 77.
74 (77%) 75.:
46 (74%) 64.:
107 (91%) 76.4
87 (78%) 71.,
66 (89%) 82.4
71 (81%) 74.
38 (88%) 61.'
19 (79%) 65.'
171 (87%) 75.4
10 (62%) 66.'
13 (81%) 76.
166 (86%) 78..
28 (78%) 55.'
190 (86%) 74.'
4 (44%) 75.'
38 (72%) 57.
156 (89%) 78.
190 (85%) 75.
3 (60%) 66.
179 (85%) 73.
15 (68%) 85.
116 (83%) 76.
78 (87%) 72.
99 (84%) 74.
95 (85%) 75.
45 (88%) 78.
48 (82%) 75.
108 (86%) 78.
86 (84%) 69.
92 (87%) 71.
86 (83%) 74.
16 (80%) 93.
71.3 73.1
67.5 84.1
78.7 83.9
37.5 70.0
41.7 65.6
80.5 78.2
70.3 71.3
65.8 79.3
76.2 79.9
5 66.0 71.3
3 71.3 59.4
60.0 80.0
3 77.3 76.8
3 70.9 74.5
3 64.3 64.8
4 72.0 80.5
7 69.9 65.3
4 79.4 86.0
3 72.3 74.6
5 61.5 66.3
7 52.6 39.7
0 71.7 75.2
7 - 53.6
9 76.9 72.2
3 74.6 74.4
9 55.9 69.0
7 71.6 74.8
0 75.0 40.0
5 57.4 62.6
6 74.7 76.4
2 72.1 74.1
7 66.7 40.0
8 70.4 74.1
.7 85.7 67.0
.2 72.4 71.8
.7 70.6 75.8
.0 68.4 72.1
.5 75.5 75.0
.8 78.8 78.6
.8 75.8 72.4
.5 76.3 74.8
.0 65.2 72.4
.4 69.0 72.2
.3 69.7 71.1
.8 93.8 90.0
-
- 84.0
_
- 14.8
Table II Patients relapsing from previous radiotherapy
Total
Stagea I
II
III
IV
A
B
Age < 26
26-39
40-59
>59
aStage attributed by addii
Remission Survival
No. of 5 years 10 years 5 years 10 years
pts CR(%) % % % %
55 50 (91%) 80.7 76.4 71.3 66.7
7 7 100 100 100 100
8 5 50 50 42.9 42.9
24 22 95 87.7 78.0 73.1
16 16 61.1 61.1 60.9 50.8
42 38 85.5 80.2 74.3 68.1
13 12 66.7 66.7 61.5 61.5
12 11 90.0 75.0 82.5 73.3
29 26 71.8 71.8 74.7 74.7
11 10 88.9 88.9 63.6 50.9
3 3 - - - -
ng all sites of disease including presentation and first relapse.
65.2
73.5
79.5
46.7
52.5
67.5
65.8
70.5
77.8
58.2
51.6
53.3
72.5
70.7
50.9
73.5
56.5
86.0
68.0
39.6
21.7
66.2
53.6
72.2
70.4
48.2
66.5
40.0
46.9
72.0
66.0
40.0
66.2
60.3
65.6
66.5
64.0
66.8
65.1
68.6
71.6
59.1
64.1
67.1
69.8
75.8
9.9
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Figure 1 a, Actuarial probability of remaining in remission for
those patients who entered CR after ChlVPP who had no
previous treatment (NPT: 194 patients) or who had previous
radiotherapy (RT: 50 patients). Vertical marks indicate censored
patients. b, Actuarial probability of survival after ChlVPP
chemotherapy for patients who had no previous treatment (229
patients) or had previous radiotherapy (55 patients). Vertical
marks indicate censored patients.
Table III Significance levels of prognostic factors on univariate
analysis for previously untreated patients
5 years relapse
CR from CR Survival
Age NS 0.039 > 0.001
Stage 0.013 NS 0.007
<III v IV (IV worse)
A v B (B worse) 0.007 NS 0.001
Lung (worse) 0.028 NS 0.034
Marrow (worse) 0.003 NS 0.084
Liver NS 0.039 0.035
Number of nodal NS 0.076 NS
sites < 3 v 3
Achieving CR - - <0.001
Lymphocytes 0.028 NS 0.018
<l x 109/l
Sex, bone disease, histology, pleural effusion, ESR, haemoglobin,
gamma GT, transaminase were not sigificant at the 5% level in this
analysis.
nostic influence of age lies in the increased risk of death in
remission for those over 40 years (3 of 174 under 40 years vs
14 of 70 over 40 years) and 7 of the deaths in CR over 40
years of age were early (less than 1 year following the start of
ChlVPP). Five of these were due to infection. The increased
risk of death in remission is significant (P<0.00001) and
together with a marginally higher relapse risk (P = 0.039)
results in a highly significant reduction in survival for older
patients.
Sex The series contains more men (55%) than women
(44%) but there is no significant difference in CR, relapse,
survival or death in remission.
Histology The expected excess of nodular sclerosis subtype
(60%) over mixed cellularity (31%) and lymphocyte
predominant (5%) or depleted (4%) is seen and NS patients
are younger (median 29 years vs median 35 years for MC,
P = 0.0085). Most NS cases were classified as mixed cellular
a
CD 100
.' 90- kl- h
80 L _
E c 70
l-
,- A~60-'
U
50+.aoE
= a) 40 -
.' 30-
.0
o 20-
0- 10
S-
< 26
26-39
40-59
> 60
0, 100
.' 90C
X 80
E
o 70
i 60CD en
> 50
=. Q) 40
.0CU .E 30-
.0
O 20
(L 10
o 0
0 1 2 3 4 5 6 7 8 9 1011121314
Time since ChIVPP (years)
b
100 r
90.
80 E
70L- --,_ --_--_
60-_ 26-39
50 -
40 >604-59i
30 -
20 -
10 -
0 I
0 1 2 34 5 6 7 891011121314
Time since ChIVPP (years)
CU
L-
Q3
co
c
d
100 -,-
90 -
80 -
70 -
60 -
50 -
40 -
30
20
10
01
0
A
B
C
.C
._
E
0)
0aZ '.
m
._
.01
20
1 2 3 4 5 6 7 8 9 10111213 14
Time since ChIVPP (years)
B
1 2 3 4 5 6 7 8 9 101112 13 14
Time since ChIVPP (years)
e
100 -
90 -
80 -
70 -
60 -
50 -
40 -
30 -
20 -
10 -
0
C
-I ---
I
1 2 3 4 5 6 7 8 9 1011 121314
Time since ChIVPP (years)
f
100 -
> 90
>80
: 70-
iO 60-
> 50
:LI
D 40-
.O 30-
° 20-
o10
0 1 2 3 4 5 6 7 8 9 1011121314
Time since ChIVPP (years)
Figure 2 a, Actuarial probability of remaining in remission after ChlVPP chemotherapy for those patients who entered CR
divided according to age. The curves are labelled with age grouping in years. No previous therapy. b, Actuarial probability of
survival after ChlVPP chemotherapy divided according to age. The curves are labelled with age groupings in years. No previous
therapy. c, Actuarial probability of remaining in remission after CR. A vs B stage. No previous therapy. d, Actuarial probability of
survival. A vs B stage. No previous therapy. e, Actuarial probability of remaining in remission after CR. Stage I and II (solid line),
II (dashed line), IV (dot-dash). No previous therapy. f, Actuarial probability of survival. Stage I and II (solid line), II (dashed line),
IV (dot-dash). No previous therapy.
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content for the nodules (77%). Overall the histological sub-
type did not influence outcome. Although the relapse rate in
the small number of LD patients was high (62.5% relapsed
at 10 years) this did not achieve significance.
Stage The significance of stage in this series is likely to be
diluted since lower stage cases were selected for
chemotherapy by their poor prognostic features. If stage
I-III patients are compared to stage IV then a highly
significant effect on survival is seen (P<0.007) which results
from lower CR rates (P = 0.013), and somewhat more
relapses and deaths in remission (not significant). Patients
with B symptoms have worse survival due mainly to a lower
CR rate (Figure 2c-f).
Sites of disease The presence of lung, liver or marrow
disease as well as having more than three involved nodal sites
predicted lower survival compared to patients without any of
these factors. For lung and marrow disease this was due to
lower CR rate and more relapse whereas for liver disease
only the relapse rate was significantly higher at P<0.05.
Lymphocyte count An absolute lymphocyte count of less
than 1 x 1091-l was associated with a lower CR rate and
survival.
The effect of previous radiotherapy was then analysed by
univariate analysis of the whole patient group (284 patients).
Previous radiotherapy was not a significant factor predicting
response, relapse or survival. The number of courses of
ChlVPP required to achieve CR varied between 1 and 9 with
a median of 3 courses. The number of courses required to
achieve CR was not a significant predictor of relapse or
survival.
Multivariate analysis
The multivariate analysis was performed in 284 patients and
included all the variables listed for univariate analysis except
for lymphocyte count (data inadequate).
The factors which independently predicted for improved
survival were achieving a complete remission, younger age,
absence of symptoms, and absence of lung, liver and marrow
disease. The individual visceral sites of disease were not
significant factors. If remission status was removed from the
analysis then the same other factors remained significant.
Among patients who entered CR, relapse was less likely in
patients who had no lung, liver or marrow disease and in
those who had less than 3 nodal sites. Among the CR
patients, factors predicting survival were age and sites of
disease reflecting the importance of age in predicting death in
remission.
Toxicity
The toxicity of the regimen was recorded retrospectively for
each course in each patient. This is summarised in Table IV
for the maximum recorded toxicity on any course in any
patient. Acute toxicity was very modest. Moderate degrees of
myelosuppression occurred but in a minority of patients;
nausea and vomiting were mild and uncommon; alopecia or
moderate neuropathy were rare. Two patients died of infec-
tion during their ChlVPP chemotherapy. They were not
leucopenic.
Second malignancies
With median follow up of 92 months, we can now comment
on the rate of second malignancy. Two cases of acute
myeloid leukaemia were seen at 7.5 and 8.7 years in patients
who had received 9 and 16 courses of ChlVPP respectively
without radiotherapy and without relapse. The actuarial risk
of a secondary leukaemia is 2.7% at 10 years. Twelve other
second cancers were noted: one malignant melanoma, one
stomach cancer, two carcinoma of bronchus, one non-
Table IV World Health Organization graded toxicity
% patients
I II III IV
Anaemia 20 9 0 0
Leukopenia 21 20 7 2
Thrombocytopenia 8 10 4 0.5
Nausea and Vomiting 18 13 1.5 0.5
Alopecia 5 1.5 0.5 0
Neuropathy 11 3 0 0
Infection 8 9 1.5 1.5
Diarrhoea 2.5 0.5 0 0
Stomatitis 1.5 1 0 0
Hodgkin's lymphoma, one breast cancer, one pancreatic
cancer and five basal cell carcinomas. The actuarial risk of
any second malignancy is 8.3% at 10 years.
Dose reduction and delay
Details of exact dosage of drug prescribed in each course was
available for 209 patients of the 229 who had received no
previous treatment. The number with any reduction for each
course is shown in Table V together with the proportion of
cases for whom treatment was delayed. These represent a
very small proportion of cases and the prognostic significance
of reduction and delay in dosage has not been analysed.
Cause of death
Eighty-eight patients have died in the whole series (284
patients) of whom 38 were considered to have died of pro-
gressive Hodgkin's disease only. Twenty-nine more patients
had active Hodgkin's disease when they died but among
these 3 died of a second malignancy, one myocardial infarc-
tion, one pulmonary embolus, two of complications of
autologous bone marrow transplantation as salvage therapy
and 22 of infection. Among these 22 patients, 20 had
relapsed at least once while two patients died of intercurrent
infection during their first course of ChlVPP.
Sixteen patients died during complete remissions of their
Hodgkin's disease. Seven died of infection within one year of
their chemotherapy and these deaths may be attributed to
disease and treatment related immunosuppression. One died
of late complications of autologous bone marrow transplant-
ation. Eight patients died of miscellaneous causes which were
not apparently linked to Hodgkin's disease or treatment.
Figure 3 is a partial cumulative probability plot relating
survival to cause of death. The majority of patients died of
or with active Hodgkin's disease and among those who died
in remission, immunosuppression was the most important
factor. Second malignancies - only some of which may be
linked to treatment - were only a minor cause of death in
this series (Figure 3).
Discussion
The results described for the efficacy of the ChlVPP regimen
in this single institution series compare favourably with any
previous results described for the combination chemotherapy
of advanced Hodgkin's disease with MOPP or regimens
Table V Dose reduction or delay
Course
1 2 3 4 5 6
% of pts with any 6 13 13 12 16 15
dosage reduction
% of pts with I week - 4 7 4 11 5
delay
% of pts with 2 weeks - 6 4 6 7 10
delay
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Figure 3 Actuarial probability of survival according to cause of
death. Curve (a) shows deaths due to active HD and all other
deaths are censored. In curve (b) deaths due to second malig-
nancy occurring patients with active HD are added to those in
curve (a) showing the increment in deaths due to this cause. In
curve (c) the deaths in CR excluding those due to second malig-
nancies are added to those shown in curve (b). In curve (d) all
deaths are shown, those due to second malignancy in CR are
added to those shown in curve (c). The difference between (c) and
(d) may be taken to indicate the difference in outcome for HD
patients resulting from all second cancers only some of which are
due to the carcinogenic effect of ChlVPP.
derived from it. In the present study, the complete remission
rate was 85% among patients who had had no previous
treatment with a 5-year probability of remaining in complete
remission of 74%. In a recent review of the outcome of
treatment with MOPP and its variants, the range of complete
remissions reported was from 62 to 82% with actuarial 4-
year relapse-free survival of between 50 and 80% of these
patients who achieved CR (Selby et al., 1987). Our results are
in keeping with long term outcomes reported for 54 patients
treated with ChlVPP in Southampton (McKendrick et al.,
1989). In a recent update of the 198 patients originally
treated with MOPP in the classic series from the National
Cancer Institute (US) the revised complete remission rate was
84% with 66% patients remaining relapse free (Longo et al.,
1986).
We emphasise that comparisons between series in different
insititutions must of course be interpreted very cautiously
because of differing patient populations accumulated into
multi institutional or single institutional studies of this kind.
For instance, over 50% of our patients were free of B
symptoms whereas only 12% of NCI patients were symptom-
free. It is not possible to compare the series by examining
published reports in a conclusive way. Even a meta-analysis
of results in a single database may not be sufficient. How-
ever, a randomised prospective trial in which mustine-
containing combination chemotherapy (MOPP) and chloram-
bucil-containing chemotherapy (LOPP) were compared show-
ed no advantage to the use of the mustine based treatment
(British National Lymphoma Investigation, 1986). This trial
supports the equivalent efficacy of mustine and chlorambucil.
Even though the overall results were poor, they were similar
in each arm of the trial. The literature contains at least four
trials in which mustine-containing regimens have been com-
pared to regimens containing other alkylating agents (Bake-
meier et al., 1984; reviewed by Selby et al., 1987). In no case
was mustine found to be more effective than the alternatives.
We feel that all of the available data support our view that
alternative alkylating agents, including chlorambucil, are
as effective as mustine in combination chemotherapy for
Hodgkin's disease.
The acute toxicity described in this paper is substantially
less than the reported acute toxicity of MOPP (for review see
Selby et al., 1987). Myelosuppression, nausea and vomiting,
neuropathy and alopecia are substantially lower with chlor-
ambucil based combination chemotherapy and the need for
venous access for the administration of mustine and the
complexities of the rapid administration of mustine before
chemical degradation occur are avoided with Ch1VPP. We
are reassured that the long term observations in this study
suggest that chlorambucil based combination chemotherapy
does not appear to be more leukaemogenic or carcinogenic
than mustine-based combination chemotherapy for Hodg-
kin's disease. The observed 10-year actuarial risk of acute
leukaemia in this series was 2.7%, both cases occurring in
patients who had chemotherapy without radiotherapy. The
literature contains figures for 10 year leukaemia risks of
1.2-15.6% for all patients who have chemotherapy with
MOPP or its variants (Tucker et al., 1988; Colman & Selby,
1987).
The use of mustine based combination chemotherapy is
now inappropriate in the management of Hodgkin's disease
and owes more to tradition than to clinical science. There are
equally effective alternative alkylating agents and among
these, chlorambucil is one less toxic choice.
The ChlVPP regimen can be given in full doses and with-
out delay to the majority of patients which may be in part
responsible for the observed efficacy. The small number of
patients for whom dose reductions or delays are necessary
precludes a formal analysis of the intensity of treatment as a
determinant of outcome in this study. The rather lower
complete remission and survival rates observed with other
chlorambucil based regimens which have lower doses of
chlorambucil and procarbazine (British National Lymphoma
Investigation, 1986) suggest that the treatment should be
used in the doses described in this paper without dose reduc-
tion or modification if this can be avoided.
The factors which we have observed to influence the out-
come of treatment with the ChlVPP regimen are broadly in
keeping with those seen in other series with other regimens
(see Selby et al., 1987). Age and disease affecting liver, lung
and bone marrow are powerful predictors of outcome and
achieving CR is the most important determinant of survival.
Some differences exist between the importance of the factors
described here and important prognostic factors found
elsewhere in the literature (Wagstaff et al., 1988; reviewed by
Selby et al., 1987). These differences are more likely to be due
to differing patient populations and selection together with
differing institutional practice for investigation and data col-
lection than to be due to any real biological differences. For
instance, Wagstaff et al. (1988) found age, sex, lymphocyte
count and stage to be independent indicators of survival in
the Barts/Christie series. We were unable to include lympho-
cyte count in our multivariate analysis because our data were
incomplete. We found no difference in survival according to
sex on univariate or multivariate analysis. We cannot fully
explain the discrepancy but the patient populations differ in
stage and treatment so that all comparisons are tentative.
For these reasons we do not propose to develop any prog-
nostic models or indices based upon the observations in the
present series.
The development of ChlVPP combination chemotherapy
has reduced the toxicity and need for hospitalisation of
patients undergoing chemotherapy for Hodgkin's disease. It
can be given easily, routinely and safely in outpatients and
many patients continue to work normally. This regimen is,
however, associated with secondary acute leukaemia in a
small number of cases in this series and is associated with
infertility in the majority of men and a minority of younger
women (Sutcliffe, 1987).
The principal problem in the future development of
chemotherapy for Hodgkin's disease remains the need for
more effective treatment which will reduce the 30-50% of
patients whose disease is not cured by existing regimens.
Failure to remit and early relapse are the major risks to our
patients. The advantages of adriamycin based regimens or of
alternation of alkylating agent based regimens with adria-
mycin based regimens remain uncertain but recent clinical
trials are suggesting an advantage for the use of an
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adriamycin based regimen such as ABVD either alone or in
alternation with MOPP or its variants (Bonnadonna et al.,
1985; review by Selby et al., 1987). In addition the use of
high dose treatment with autologous bone marrow grafting is
allowing salvage of a proportion of patients who relapse
from conventional dosage chemotherapy (Russell et al., 1989;
Zulian et al., 1989). Chlorambucil based combination chemo-
therapy represents a substantial step towards reducing the
burden of combination chemotherapy upon the patient with
advanced Hodgkin's disease but there remain many problems
to be solved.
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